EGM
LENZ

Engineers Gate Manager’s LENZ Therapeutics LENZ Stock Holding History

Engineers Gate Manager’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$295K Buy
32,243
+1,185
+4% +$16.6K ﹤0.01% 1714
2025
Q4 		$497K Buy
+31,058
New +$905K 0.01% 1365
2024
Q3 		– Sell
-14,654
Closed -$253K – 2460
2024
Q2 		$253K Buy
+14,654
New +$256K 0.01% 1547

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Engineers Gate Manager's LENZ Position: Q1 2026 in Review

Engineers Gate Manager increased its LENZ Therapeutics (LENZ) stake by 3.8% in Q1 2026, buying an estimated $16.6K and bringing the position to 32,243 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

Engineers Gate Manager first reported a position in LENZ in Q2 2024 and has held it in 3 quarters since. The position peaked at $497K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Engineers Gate Manager held 32,243 shares of LENZ Therapeutics worth $295K as of Q1 2026.
  • Engineers Gate Manager bought 1,185 LENZ Therapeutics shares in Q1 2026, an estimated $16.6K.
  • LENZ Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q1 2026, its #1714 holding.
  • Engineers Gate Manager first reported a position in LENZ Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Engineers Gate Manager's LENZ Therapeutics position peaked at $497K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.